Aldeyra Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 9, 2026, following the Company's 2026 Annual Meeting of Stockholders. The filing details the appointment of a new director, the results of stockholder votes, and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Governance Actions
- Director Appointment: The Board appointed Darlene Deptula-Hicks as a Class III director, with a term expiring at the 2029 annual meeting. She was also appointed Chair of the Audit Committee.
- Qualifications: Ms. Deptula-Hicks is deemed independent under SEC and Nasdaq rules and qualifies as an audit committee financial expert.
- Compensation Package:
- Initial grant: Non-statutory stock option for 94,313 shares (vesting ratably over three years).
- Annual cash fees: $40,000 for director service and $7,500 for Audit Committee Chair service.
- Annual equity grants: Options to purchase approximately $130,000 of stock for director service and $15,000 for Audit Committee Chair service (vesting in full after one year).
- Indemnification: An indemnification agreement was entered into, protecting Ms. Deptula-Hicks to the fullest extent permitted under Delaware law.
Stockholder Voting Results
Of 60,321,068 shares entitled to vote, 44,271,484 shares (approximately 73.4%) were represented, constituting a quorum.
| Proposal | Votes For | Votes Against | Votes Withheld/Abstaining | Broker Non-Votes |
|---|---|---|---|---|
| 1. Election of Director (Todd C. Brady) | 23,026,101 | N/A | 1,081,762 | 20,038,067 |
| 2. Ratification of Auditor (BDO USA, P.C.) | 43,693,772 | 321,501 | 130,657 | N/A |
| 3. Advisory Vote on Executive Compensation | 19,477,504 | 4,543,221 | 87,138 | 20,038,067 |
Outlook, Risks, and Unusual Items
The filing does not contain management commentary on future business outlook, specific risks, or unusual items. It references a press release (Exhibit 99.1) regarding the director appointment but does not include its text.
Key Facts for Investor Verification
- Verify the impact of the new Audit Committee Chair on the Company's financial oversight and reporting processes.
- Review the 2026 Proxy Statement (filed April 27, 2026) for detailed terms of the non-employee director compensation program.
- Note the significant number of broker non-votes (20,038,067) on the director election and executive compensation proposals, indicating shares held by brokers that did not receive voting instructions.
- Confirm the independence and financial expertise of the new director as disclosed in the filing.